Acadian Asset Management
IMDX

Acadian Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Acadian Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-605
Closed -$25K – 2017
2019
Q3 		$25K Hold
605
– – ﹤0.01% 1696
2019
Q2 		$30K Buy
+605
New +$50.3K ﹤0.01% 1554

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management's IMDX Position: Q4 2019 in Review

Acadian Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2019, closing a stake of 605 shares — an estimated $25K sold.

Acadian Asset Management first reported a position in IMDX in Q2 2019 and held it in 2 quarters. The position peaked at $30K in Q2 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q4 2019.

  • Acadian Asset Management reported no remaining Insight Molecular Diagnostics position as of Q4 2019 after selling out during the quarter.
  • Acadian Asset Management sold 605 Insight Molecular Diagnostics shares in Q4 2019, an estimated $25K.
  • Acadian Asset Management first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 2 quarters.
  • Acadian Asset Management's Insight Molecular Diagnostics position peaked at $30K in Q2 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2019.

Based on Acadian Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.